OpenAlex
PricingAboutJobs
Log inGet started
Work

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

HTML

Year: 2011
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Oncology
DOI: 10.1016/s1470-2045(11)70124-3
Authors: Sylvie Négrier, Gwenaëlle Gravis, David Pérol, Christine Chevreau, Rémy Delva, Jacques-Olivier Bay, Ellen Blanc, Céline Ferlay, Lionnel Geoffrois, Frédéric Rolland, Eric Legouffe, Emmanuel Sevin, Brigitte Laguerre, Bernard Escudier
Institutions: Centre Léon Bérard, Institut Paoli-Calmettes, Institut Claudius Regaud, Centre Jean Perrin, Centre François Baclesse, Centre Eugène Marquis, Institut Gustave Roussy
Language: English

Topic: Renal cell carcinoma treatment
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: temsirolimus, bevacizumab, sunitinib, interferon-alpha, advanced renal cell carcinoma, metastatic renal cell carcinoma, mTOR inhibitors, VEGF receptor inhibition, combination therapy, progression-free survival, targeted therapy, overall survival, quality of life, adverse events, proteinuria, thrombocytopenia
SDG: Good health and well-being

Open Access status: closed

Funders: Kidney Cancer Association, Ministère des Affaires Sociales et de la Santé, Wyeth Pharmaceuticals
OpenAlex ID: W2024586523
FWCI: 19.61
Cites: 42
Cited by: 257
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms